ORCHID PHARMA LIMITED (ORCHPHARMA)

NSE: ₹834.85
BSE: ₹834.35
Stock Performance
Corporate Announcements
Update Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited And Orchid Pharma Limited

Update for receipt of copy of order related to scheme of Amalgamation of Dhanuka Laboratories limited and Orchid Pharma limited

2026-06-12 12:57:49
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order

Disclosure regarding the order passed by Goods and Service Department.

2026-06-11 15:46:14
Update Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited (''Amalgamating Company'') With Orchid Pharma Limited (''Amalgamated Company'') And Their Respective Shareholders And Creditors (''The Scheme'') Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

In continuation to our earlier intimation dated March 18, 2026, with respect to merger petition, we would like to inform that Hon'ble National Company Law Tribunal ("NCLT") on June 05, 2026 i.e. today, has allowed our petition sanctioning the scheme of Amalgamation and Arrangement of Dhanuka Laboratories Limited with Orchid Pharma Limited and their respective Shareholders and Creditors, by virtue of which, the Amalgamating Company would stand transferred to and vested in, or deemed to have been transferred and vested in Amalgamated Company on a going concern basis.

2026-06-05 17:29:43
Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Transcript of Analysts/ Investor Earning Call held on May 26, 2026 for the Quarter and Financial Year ended on March 31, 2026

2026-06-01 18:41:28
Compliances-Reg.24(A)-Annual Secretarial Compliance

Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026.

2026-05-30 14:46:06
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet – Outcome

Investor / Analysts call recording for the Quarter- 4 and Financial year ending March 31, 2026.

2026-05-26 19:43:10
Announcement under Regulation 30 (LODR)-Investor Presentation

Investor Presentation for Quarter- IV and Financial year ended on March 31, 2026.

2026-05-26 14:18:02
Appointment Of Internal Auditor Of The Company

Appointment of Internal Auditor of the Company.

2026-05-25 21:13:22
Statement Of Deviation Or Variation For The Quarter And Financial Year Ended On March 31, 2026

Statement of Deviation or Variation for the Quarter and Financial Year ended on March 31, 2026

2026-05-25 19:58:58
Board Meeting Outcome For Outcome Of Board Meeting For Considering And Approving Annual Audited Financial Results For The Quarter And F.Y. Ended On March 31, 2026

Board Meeting Outcome for Outcome of Board Meeting for considering and approving Annual Audited Financial Results for the Quarter and Financial Year ended on March 31, 2026

2026-05-25 19:47:56

Quarterly Financials

Consolidated Standalone
Particulars Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 182.92 198.76 220.59 217.10 244.41 222.70 217.34 237.48 172.93 193.52 207.27 237.61
YOY Revenue Growth % 39.65% 20.28% 38.08% 3.43% 33.61% 12.05% -1.47% 9.39% -29.25% -13.1% -4.64% 0.05%
Other Income 1.89 8.36 7.62 13.36 7.57 7.52 8.49 3.90 11.45 10.77 5.61 7.34
Total Income 184.81 207.11 228.21 230.46 251.98 230.22 225.83 241.38 184.38 204.30 212.88 244.95
Total Expenses + 174.03 187.09 198.01 200.08 223.86 204.32 203.38 222.28 170.67 207.63 217.91 222.70
Cost of Materials Consumed 118.41 117.86 135.62 156.47 152.77 153.72 142.02 136.94 110.16 112.27 118.97 120.95
Employee Benefit Expense 16.22 17.56 19.14 17.57 22.00 20.06 22.06 22.24 21.61 24.85 24.13 20.88
Other Expenses 32.49 35.55 44.12 42.49 39.66 41.14 44.13 49.24 38.28 37.64 38.43 38.51
Operating Profit 8.89 11.67 22.58 17.02 20.55 18.38 13.96 15.20 2.26 -14.11 -10.64 14.91
OPM % 4.9% 5.9% 10.2% 7.8% 8.4% 8.3% 6.4% 6.4% 1.3% -7.3% -5.1% 6.3%
Profit Before Tax + 10.78 20.02 30.19 30.38 28.12 25.90 22.45 19.09 13.71 -3.33 -12.15 22.79
Tax Expense 1.37 0.22 0.76 -2.57 -1.23 -1.34 1.67 -3.20 -1.20 2.39 0.47 -0.99
Tax % 12.7% 1.1% 2.5% -8.5% -4.4% -5.2% 7.5% -16.8% -8.7% - - -4.4%
Profit After Tax 9.40 19.80 29.43 32.96 29.35 27.24 20.78 22.29 14.91 -5.72 -12.61 23.78
EPS (Basic) 1.85 4.30 6.18 6.81 5.79 5.37 4.10 4.40 2.94 -1.13 -2.49 4.69

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
Revenue from Operations 811.33 921.93 819.37 665.90 559.56 450.06
YOY Revenue Growth % -12% 12.52% 23.05% 19% 24.33% -
Other Income 35.17 27.47 30.86 19.43 9.00 15.23
Total Income 846.50 949.40 850.23 685.33 568.56 465.29
Total Expenses + 818.91 853.84 758.29 669.29 628.98 560.54
Cost of Materials Consumed 462.34 585.46 528.35 406.10 340.62 245.60
Employee Benefit Expense 91.47 86.36 69.64 65.35 63.28 67.11
Other Expenses 152.85 174.17 154.59 132.31 133.11 104.67
Operating Profit -7.58 68.09 61.08 -3.39 -69.42 -110.47
OPM % -0.9% 7.4% 7.5% -0.5% -12.4% -24.5%
Profit Before Exceptional 27.59 95.56 91.95 16.04 -60.42 -95.25
Exceptional Items -6.57 0.00 0.00 39.21 0.00 0.00
Profit Before Tax + 21.02 95.56 91.95 55.25 -60.42 -95.25
Tax Expense 0.47 -4.09 -0.22 8.93 -58.47 21.28
Tax % 2.2% -4.3% -0.2% 16.2% - -
Profit After Tax 20.55 99.66 92.17 46.32 -1.95 -116.53
EPS (Basic) 4.05 19.65 19.06 11.35 -0.48 -28.55

Balance Sheet

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
ASSETS
Non-Current Assets + 1,227.01 880.50 763.12 724.20 660.68 687.40
Property, Plant & Equipment 613.22 631.59 618.92 572.71 583.37 670.08
Capital Work in Progress 340.52 64.49 16.39 46.46 9.78 7.43
Non-Current Investments 52.71 49.67 45.82 44.44 45.49 0.40
Goodwill 0.00 1.13 0.00 0.00 0.00 0.00
Other Intangible Assets 0.60 0.00 0.64 0.39 0.34 0.37
Current Assets + 683.61 807.42 790.75 501.01 436.60 429.01
Inventories 256.41 326.37 264.23 228.74 172.66 152.89
Trade Receivables 263.87 241.83 195.55 215.19 170.57 135.70
Cash and Cash Equivalents 7.01 21.11 3.60 22.60 4.31 15.69
Current Investments 0.00 0.00 0.00 0.00 0.00 15.02
LIABILITIES & EQUITY
Total Equity 1,287.79 1,267.29 1,169.47 688.65 647.38 652.91
Equity Share Capital 50.72 50.72 50.72 40.82 40.82 40.82
Other Equity 1,237.07 1,216.57 1,118.75 647.83 606.56 612.09
Non-Current Liabilities 344.16 135.06 124.43 164.67 222.40 442.26
Current Liabilities 278.97 285.57 259.97 371.89 240.78 142.08
Total Liabilities 623.13 420.63 384.41 536.56 463.18 584.34

Cash Flow Statement

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
Cash from Operating Activities 101.20 19.22 125.99 18.58 88.95 28.92
Cash from Investing Activities -285.27 -26.93 -312.03 -31.46 116.46 94.57
Cash from Financing Activities 169.98 25.22 167.04 31.17 -216.80 85.17
Net Increase/Decrease in Cash -14.10 17.51 -19.00 18.29 -11.39 208.66